Maegim

Stock search

Search by company name, 6-digit code, or Korean initials (e.g. ㅅㅅㅈㅈ)

☆한국어

SEOUL PHARMA CO.,LTD

서울제약018680KOSDAQSector: Pharma & Biotech
₩1,9500.26%Market cap ₩22.7BAs of Sep 1, 2026 close · updated once daily
Market cap
₩22.7B
#1575 in KOSDAQ
30.2x
Sector median 16.3x (profitable cos.)
0.55x
Sector median 1.61x
0.0%
Sector median 0.0%
B
Grade B52.3 ptsTop 50% of 2,523 graded stocksPreviously CMethodology v2.0
Financial strength
51.3/100
Growth momentum
20.5/100
Price attractiveness
78.3/100
Shareholder Return
37.5/100

As of Sep 1, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

How to read this grade
SABCurrentCDF

Toward S means a higher total-score band; toward F, a lower band. Badges are distinguished by ink intensity and shape (fill, outline, dashed) — never by hue.

Maegim maps a total score — built from sector-relative percentile scoring — onto fixed, predefined thresholds to assign one of six bands, S to F. This stock is scored by the same formula as all 2,523 graded stocks and is currently in band B with a total score of 52.3 points.

How grades are computed →What grades do and don’t mean →What the grade does not reflect →

Position within sector

Mechanically selected indicators in the top or bottom 30% of sector percentiles · among 250 stocks in Pharma & Biotech

1-year closing price

Loading closing price history…
 
Low ₩1,945High ₩3,320
Latest close
Price change by period
1W
1.10%
1M
2.00%
3M
12.90%
1Y
40.60%

As of the Sep 1, 2026 close · updated once daily · a factual record computed from closing prices only; dividends are not included, and this is not a buy or sell signal.

1

Financial strength

51.3/100
How much debt does it carry relative to equity?
74.8%
Sector median 51.6%
Sector lowhighBottom 35% in sector
Can it cover what's due within a year?
228.3%
Sector median 191.7%
Sector lowhighTop 41.5% in sector
How much of revenue becomes profit?
-2.5%
Sector median -2.4%
Sector lowhighBottom 49.8% in sector
How much did it earn on its own capital?
1.8%
Sector median -4.5%
Sector lowhighTop 38.3% in sector

Source filing: annual report (separate) — view original ↗

2

Growth momentum

20.5/100
How much did revenue grow in a year?
-2.7%
Sector median 6.4%
Sector lowhighBottom 28% in sector
Has it grown steadily over three years?
1.4%
Sector median 4.9%
Sector lowhighBottom 34.9% in sector
Did core profits grow in a year?
-183.7%
Sector median 3.6%
Sector lowhighBottom 6.9% in sector
Are core profits higher than three years ago?
-173.6%
Sector median 3.5%
Sector lowhighBottom 12.1% in sector

Financial trend

Revenue

Growth & margin

Revenue growth Operating margin

Year over year — alongside the sector median

This stock Sector median

A factual chart of confirmed annual results from annual reports — the same source as the grading indicators. Not a buy or sell signal.

Source filing: annual report (separate) — view original ↗

3

Price attractiveness

78.3/100
Is the price expensive relative to earnings?
30.2x
Sector median P/E of profitable peers 16.3x · 58% loss-making
Sector lowhighTop 29.8% in sector
Is the price expensive relative to book value?
0.55x
Sector median 1.61x
Sector lowhighTop 13.6% in sector

Valuation uses the Sep 1, 2026 close and market cap

4

Shareholder Return

Single-indicator axis37.5/100
Does the company actually pay dividends?
0.0%
Sector median 0.0%
Sector lowhighBottom 37.5% in sector

Source filing: annual report (separate) — view original ↗

Financial checklist

Based on the FY2025 annual report · year-over-year comparison · determined on Sep 2, 2026

Of 9 items: 6 met · 3 not met · 0 not computable

Not metMetNot computable

Positive net income
Whether net income (attributable to owners where available) is above zero.
Met
₩754M
Positive operating cash flow
Whether cash flow from operations is above zero.
Met
₩1.9B
Return on assets up
Whether net income over beginning total assets rose from the prior year.
Not met
2.7% → 1.1%
Operating cash flow exceeds net income
Whether operating cash flow is greater than net income.
Met
₩1.9B vs ₩754M
Liabilities-to-assets ratio down
Whether total liabilities as a share of total assets fell from the prior year.
Met
43.9% → 42.8%
Current ratio up
Whether current assets over current liabilities rose from the prior year.
Met
228.1% → 228.3%
Shares outstanding not increased
Whether common shares issued did not increase from the prior year. Increases from bonus issues and stock dividends are also counted.
Met
11,659,319 → 11,659,319
Operating margin up
Whether operating income over revenue rose from the prior year.
Not met
2.9% → -2.5%
Asset turnover up
Whether revenue over beginning total assets rose from the prior year.
Not met
0.85x → 0.73x

A record of facts determined by fixed rules from the financial statements in the latest annual report. Not used in grading, and not a buy or sell signal. Source filing: annual report (separate) — view original ↗

Grade change history

Jul 23, 2026B

Methodology version change (v2.0 applied)

Jul 15, 2026C→BVersion v1.1

Methodology version change (v1.1 applied)

Jul 15, 2026CVersion v1

First calculation

Grade changes are a factual record produced from public data by a fixed formula; they do not signal future changes.

Recent filings for this stock

Last 120 days · monitored filing types only
Periodic report filedAug 14, 2026Source ↗
Periodic report filedMay 15, 2026Source ↗

View in the filings calendar →